From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?

por Hashemi-Meshkini, Amir, Varmaghani, Mehdi, Yousefi, Mehdi, Yaghoubifard, Saeed, Zekri, Hedieh-Sadat, Nikfar, Shekoufeh, Kebriaeezadeh, Abbas
Publicado 2014

Developing a patient satisfaction questionnaire for services provided in Iranian community pharmacies

por Yaghoubifard, Saeed, Rashidian, Arash, Kebriaeezadeh, Abbas, Sheidaei, Ali, Varmaghani, Mehdi, Hashemi-Meshkini, Amir, Zekri, Hedieh-Sadat
Publicado 2016

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis

por Hashemi-Meshkini, Amir, Zekri, Hedieh Sadat, Karimi-Yazdi, Hasan, Zaboli, Pardis, Sahraian, Mohammad Ali, Nikfar, Shekoufeh
Publicado 2018

Pharmaceutical laws and regulations in Iran: An overview

por Zaboli, Pardis, Hashemi-Meshkini, Amir, Varmaghani, Mehdi, Gholami, Hadi, Vazirian, Iman, Zekri, Hedieh-Sadat, Eslamitabar, Shahriar, Kebriaeezadeh, Abbas
Publicado 2016

Evaluation of productivity in Iranian pharmaceutical companies: A DEA-based Malmquist approach and panel data analysis

por Varmaghani, Mehdi, Meshkini, Amir Hashemi, Farzadfar, Farshad, Yousefi, Mehdi, Yaghoubifard, Saeed, Varahrami, Vida, Darzi, Ehsan Rezaei, Anabi, Majid, Kebriaeezadeh, Abbas, Zekri, Hedieh-Sadat
Publicado 2015